Cosmax Nbt, Inc. (KOSDAQ:222040)
7,870.00
+60.00 (0.77%)
At close: May 29, 2026
Cosmax Nbt Revenue
Cosmax Nbt had revenue of 93.26B KRW in the quarter ending March 31, 2026, with 29.21% growth. This brings the company's revenue in the last twelve months to 308.56B, down -3.32% year-over-year. In the year 2025, Cosmax Nbt had annual revenue of 287.48B, down -9.59%.
Revenue (ttm)
308.56B
Revenue Growth
-3.32%
P/S Ratio
0.52
Revenue / Employee
601.49M
Employees
513
Market Cap
161.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 287.48B | -30.51B | -9.59% |
| Dec 31, 2024 | 317.99B | -15.65B | -4.69% |
| Dec 31, 2023 | 333.63B | 5.42B | 1.65% |
| Dec 31, 2022 | 328.21B | 38.86B | 13.43% |
| Dec 31, 2021 | 289.35B | 22.56B | 8.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 330.05B |
| H.PIO | 258.19B |
| DongKoo Bio & Pharma | 242.08B |
| Kyung Dong Pharmaceutical | 198.27B |
| GC WellBeing | 179.05B |
| DAE HWA Pharmaceutical | 143.42B |
| HYUNDAI BIOLAND | 135.04B |
| OPTUS Pharmaceutical | 91.62B |